Ac immune to present progress of alzheimer's disease programs targeting abeta and tau at the 15th ctad conference

Lausanne, switzerland, november 2 3 , 202 2 – ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the upcoming presentations of its vaccine technology supraantigen®, and of its anti-tau and anti-abeta investigational candidates, at the 15th clinical trials on alzheimer's disease (ctad) conference in san francisco, california (united states) and online, on november 29 – december 2, 2022.
ACIU Ratings Summary
ACIU Quant Ranking